Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on April 10, 2018. The report details the entry into a Material Definitive Agreement. Note: The request metadata references "Harrow, Inc.," but the filing text explicitly identifies the registrant as Imprimis Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a specific licensing agreement.
Material Changes and Agreement Terms
On April 10, 2018, the Company entered into an Amended and Restated License Agreement with Richard L. Lindstrom, M.D., modifying the original agreement dated April 1, 2017. The amendment facilitates sub-license and royalty agreements with the Company's subsidiary, Surface Pharmaceuticals, Inc.
- Licensed Product: KlarityTM, a topical ophthalmic solution for ocular surface protection and rehabilitation.
- Royalty Obligations: The Company must pay Dr. Lindstrom royalties ranging from 3% to 6% of net sales, dependent on the final product formulation.
- Milestone Payments:
- $50,000 upon execution of the agreement.
- $50,000 following the first $50,000 in net sales.
- $50,000 following the first $100,000 in net sales.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general risks. The text notes that the description provided is brief and does not constitute a complete description of the rights and obligations under the agreement.
Investor Verification Checklist
- Verify the total potential cash outflow for milestone payments ($150,000) against current cash reserves.
- Confirm the commercial status and sales trajectory of the KlarityTM product to assess royalty trigger timelines.
- Review the full text of the Amended License Agreement for additional obligations not summarized in this 8-K.
- Clarify the relationship and financial impact of the subsidiary, Surface Pharmaceuticals, Inc., regarding the sub-licensing arrangement.